Alembic Pharmaceuticals Reports Stable Financial Results Amid Rising Debt and Cash Flow Challenges

Alembic Pharmaceuticals has recently reported its financial results for the quarter ending June 2025, revealing a stable performance during this period. The company has experienced an adjustment in its evaluation, with its score improving to -2 from -10 over the last three months.
Key highlights from Alembic Pharma's financials indicate that the operating profit (PBDIT) reached a notable Rs 281.35 crore, marking the highest figure in the last five quarters. This positive trend in operating profit suggests a strengthening operational efficiency, as reflected in the operating profit margin, which also peaked at 16.45% during the same timeframe.

However, there are areas of concern. The interest expense for the nine-month period has risen significantly to Rs 70.30 crore, indicating a substantial increase in borrowing costs. Additionally, the annual operating cash flow has dropped to Rs 87.95 crore, the lowest in three years, suggesting challenges in cash generation from business operations. The debt-equity ratio has also reached its highest point in the last five half-yearly periods at 0.24 times, indicating increased reliance on debt financing. Furthermore, the debtors turnover ratio has slowed, now at 4.77 times, reflecting a longer duration in settling receivables.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.